Tag: Lumevoq
GenSight Biologics: new data on Lumevoq presented this week
(AOF) – GenSight Biologics today announced that new data and scientific analyzes relating to the Lumevoq gene therapy will be presented at the 50th Annual Meeting of the North American…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023 – 11/15/2023 at 6:19 p.m.
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight: the market welcomes the progress on Lumevoq
(CercleFinance.com) – GenSight Biologics jumped more than 30% on Wednesday morning on the Paris Stock Exchange after an update on its discussions with the European Medicines Agency (EMA) concerning its…
GenSight Biologics up sharply after production of 1st batch of GMP-compliant Lumevoq – 09/18/2023 at 11:06
(AOF) – GenSight Biologics (+60.78% to 0.66 euros) sees its stock skyrocket in high volumes after announcing that its production partner in the United States has successfully produced a batch…
Gensight Biologics collapses after Lumevoq clearance request withdrawn – 04/21/2023 at 14:46
Lumevoq is a gene therapy treatment for Leber hereditary optic neuropathy (LHON). (illustration photo / Photo credits: Adobe Stock – ) (AOF) – GenSight Biologics loses 65.96% to 0.8340 euro…
GenSight Biologics: Lumevoq early access data confirms clinical trials – 03/15/2023 at 09:57
(AOF) – GenSight Biologics announces that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy (LHON) and carriers of the ND4 mutation treated with lenadogene nolparvovec (or…
GenSight Biologics: presentation of data on LUMEVOQ – 03/15/2023 at 10:28
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…
GenSight Biologics: presentation of data on LUMEVOQ
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…
GenSight Biologics: positive 3-year data for Lumevoq
(CercleFinance.com) – GenSight Biologics today announces efficacy and safety results at 3 years post-injection of Lumevoq in the REFLECT phase III clinical trial. The results show the maintenance of the…
GenSight Biologics: will present data on Lumevoq – 03/10/2023 at 10:15 am
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…
GenSight Biologics: will present data on Lumevoq
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…